Jazz Pharmaceuticals plcJAZZ
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $4.44B, growing 9.2% year-over-year. TTM net income stood at $29.49M (93.9% contraction). Quarterly EBITDA was $518.00M and operating income was $336.60M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze JAZZ growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters